The FDA has issued a warning that rare but serious cases of stroke and tears in the lining of arteries in the head and neck have occurred in patients with multiple sclerosis (MS) who received treatment with alemtuzumab (Lemtrada).
The FDA has issued a warning that rare but serious cases of stroke and tears in the lining of arteries in the head and neck have occurred in patients with multiple sclerosis (MS) who received treatment with alemtuzumab (Lemtrada).
According to the agency, these adverse events can lead to permanent disability and even death. Most patients taking the treatment who developed either problem had symptoms within 1 day of receiving the treatment. One patient reported symptoms 3 days after treatment.
The FDA recommends that patients or their caregivers seek emergency treatment as soon as possible if the patient experiences signs or symptoms of a stroke or tears in the lining of head and neck arteries, which include:
They also recommend that during every alemtuzumab infusion, healthcare professionals should advise patients to seek immediate emergency medical attention if they experience symptoms of ischemic or hemorrhagic stroke or cervicocephalic arterial dissection. According to the agency, the diagnosis is often complicated because early symptoms, such as head and neck pain, are nonspecific.
Alemtuzumab gained FDA approval for relapsing forms of MS in 2014. Since its approval, the FDA has identified 13 worldwide cases of ischemic and hemorrhagic stroke or arterial dissection that occurred shortly after treatment. The FDA noted that additional cases they were not made aware of may have occurred.
The FDA added a new warning about these risks to the prescribing information drug label and to the patient Medication Guide.
Alemtuzumab is also approved under the brand name Campath, which was approved in May 2001 for B-cell chronic lymphocytic leukemia. The drug label for this indication will also be updated to include these risks.
Last month, the FDA issued a warning regarding the MS treatment fingolimod (Gilenya). They warned patients to speak with their healthcare providers before stopping the treatment due to rare cases of MS becoming worse compared with before treatment started or during treatment.
Patient-Reported Outcomes Reinforce Efficacy of Natalizumab for MS
November 21st 2023Researchers gathered data on patient-reported outcomes to support evidence for the continuation of natalizumab, a disease-modifying treatment, in the management of multiple sclerosis (MS) progression.
Read More
Timing of Neurofilament Light Changes May Predict Multiple Sclerosis Worsening
November 16th 2023The reported neurofilament light elevation preceding confirmed disability worsening events highlighted the value of NfL as an early biomarker of disability worsening and points to the existence of different windows of dynamic central nervous system pathology.
Read More
FDA Allows At-Home Dosing of Intranasal Foralumab for Multiple Sclerosis
October 23rd 2023The FDA’s decision to allow at-home dosing of intransal foralumab for patients with multiple sclerosis is likely to improve patient compliance to treatment and health outcomes, according to a recent release statement.
Read More